Want to see GB:RUA full AI Analyst Report?
RUA Stock Chart & Stats
14.00 p
-0.50 p(-3.85%)
At close: 4:00 PM EST
14.00 p
-0.50 p(-3.85%)
Day’s Range― - ―
52-Week Range10.42 p - 27.00 p
Previous CloseN/A
Volume378.53K
Average Volume (3M)148.53K
Market Cap
£15.83M
Enterprise Value6.08 p
Total Cash (Recent Filing)£3.25M
Total Debt (Recent Filing)£794.00K
Price to Earnings (P/E)―
Beta0.11
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding62,060,272
10 Day Avg. Volume90,619
30 Day Avg. Volume148,527
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.98
Price to Sales (P/S)1.57
P/FCF Ratio-23.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross Margin & Revenue ScaleSustained ~69% gross margin and multi‑year revenue scaling indicate durable product differentiation and pricing power in biomaterials. High gross margin provides structural capacity to absorb SG&A and R&D while revenue growth validates market fit and supports future operating leverage.
Conservative Balance SheetVery low leverage gives the company financial flexibility to fund operations, invest in manufacturing and R&D, and withstand cash burn without immediate refinancing pressure. A conservative capital structure reduces insolvency risk over the medium term.
Improving Operational TrendClear improvement versus prior years signals management execution on cost control and scaling. Trend improvement reduces the structural distance to breakeven and suggests that continued revenue growth could convert into sustainable profits if operating discipline continues.
Bears Say
Persistent Negative Cash FlowOngoing negative operating and free cash flow means the business is not yet self-funding and will likely require external capital if losses persist. This increases dilution or financing risk and constrains reinvestment into capacity or commercialization over the medium term.
Operating LossesA significant negative EBIT margin despite strong gross margins points to high fixed or operating costs preventing conversion of sales into earnings. Structural operating losses raise the risk that scale alone may not be sufficient without ongoing margin improvement.
Limited Scale / Concentration RiskA small organizational scale suggests execution and capacity constraints for large contracts, slower geographic diversification, and higher key‑person risk. Scaling manufacturing and regulatory support in medtech typically requires additional investment and capabilities.
RUA Life Sciences News
RUA FAQ
What was RUA Life Sciences’s price range in the past 12 months?
RUA Life Sciences lowest share price was 10.42 p and its highest was 27.00 p in the past 12 months.
What is RUA Life Sciences’s market cap?
RUA Life Sciences’s market cap is £15.83M.
When is RUA Life Sciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were RUA Life Sciences’s earnings last quarter?
Currently, no data Available
Is RUA Life Sciences overvalued?
According to Wall Street analysts RUA Life Sciences’s price is currently Overvalued.
Does RUA Life Sciences pay dividends?
RUA Life Sciences does not currently pay dividends.
What is RUA Life Sciences’s EPS estimate?
RUA Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RUA Life Sciences have?
RUA Life Sciences has 62,060,272 shares outstanding.
What happened to RUA Life Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of RUA Life Sciences?
Currently, no hedge funds are holding shares in GB:RUA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RUA Life Sciences
RUA Life Sciences plc, operating with its subsidiaries, delivers specialized polymers, various services, and finished products to the global medical device sector, spanning Europe, the United States, and other international markets. The company's operations encompass serving as a contract partner for the development and manufacturing of medical devices. Furthermore, it licenses its proprietary Elast-Eon and ECSil implantable co-polymers, which are integrated into cardiac and urological applications, including pacing leads, cardiac cannulae, and stent devices. RUA also grants licenses for its reaction injection molding technology, crucial for crafting high-precision medical device components. The firm is actively engaged in developing innovative bore polymer-sealed grafts, advanced soft tissue patches, and novel three-leaflet polymeric heart valves. Established in 1996 and based in Irvine, United Kingdom, the company adopted its current name, RUA Life Sciences plc, in June 2020, having previously been known as AorTech International plc.
Technical Analysis
Creo Medical
―
Genedrive
―
Inspiration Healthcare
―
OptiBiotix Health
―
Surgical Innovations
―